

**Silco Pharmaceuticals Limited**  
**Statement of Financial Position**  
**As at March 31, 2019**

Particulars	Amount in Taka	
	31 March 2019	30 June 2018
<b>Assets</b>		
<b>Non Current Assets</b>	<b>1,263,243,746</b>	<b>1,249,517,443</b>
Property, Plant & Equipment	1,143,508,453	1,175,166,949
Capital Work in Progress	119,735,293	74,350,494
<b>Current Assets</b>	<b>1,362,395,071</b>	<b>896,796,670</b>
Inventories	428,464,187	398,357,928
Trade Receivables	463,578,023	389,362,515
Advance, Deposits and Prepayments	110,696,553	93,413,781
Cash and Cash Equivalents	359,656,308	15,662,446
<b>Total Assets</b>	<b>2,625,638,818</b>	<b>2,146,314,114</b>
<b>Shareholders Equity and Liabilities</b>		
<b>Shareholders Equity</b>	<b>1,819,723,711</b>	<b>1,741,076,872</b>
Share Capital	643,700,000	643,700,000
Retained Earnings	1,176,023,711	1,097,376,872
Share Money Deposit (NRB)	347,485,000	-
<b>Non-Current Liabilities</b>	<b>203,969,303</b>	<b>196,477,075</b>
Deferred Tax Liability	203,969,303	196,477,075
<b>Current Liabilities</b>	<b>254,460,804</b>	<b>208,760,168</b>
Trade Payable	15,566,097	16,328,305
Creditors & Accruals	17,477,864	11,920,846
Liability for WPPF	14,154,697	8,104,940
Current Tax Liability	207,262,146	172,406,076
<b>Total Shareholders Equity and Liabilities</b>	<b>2,625,638,818</b>	<b>2,146,314,114</b>
<b>Net Asset Value (NAV) per Share</b>	<b>28.27</b>	<b>27.05</b>

The annexed notes form an integral part of these financial statements.

sd/-  
**Chief Financial Officer**

sd/-  
**Company Secretary**

sd/-  
**Managing Director**

sd/-  
**Chairman**

Dated: April 28, 2019  
Place: Dhaka

**Silco Pharmaceuticals Limited**  
**Statement of Profit or Loss and other Comprehensive Income**  
**For the period ended March 31, 2019**

Particulars	Amount in Taka		Quarterly Results	
	01/07/2018 to 31/03/2019	01/07/2017 to 31/03/2018	01.01.2019 to 31.03.2019	01.01.2018 to 31.03.2018
Sales /Revenue	707,697,127	705,057,718	240,878,442	244,235,680
Less: Cost of Goods Sold	484,654,942	482,152,749	159,282,955	159,786,321
<b>Gross Profit</b>	<b>223,042,185</b>	<b>222,904,969</b>	<b>81,595,487</b>	<b>84,449,359</b>
Less: Operating Expenses	95,419,975	95,752,400	32,166,412	34,050,136
<b>Profit from Operation</b>	<b>127,622,210</b>	<b>127,152,569</b>	<b>49,429,075</b>	<b>50,399,224</b>
Less: Financial Expenses	727,676	952,769	227,967	340,056
Add: Non-operation Income	150,360	292,168	47,105	104,278
<b>Profit before Contribution to WPPF</b>	<b>127,044,894</b>	<b>126,491,969</b>	<b>49,248,212</b>	<b>50,163,446</b>
Less: Workers' Profit Participation/Welfare Fund Expenses	6,049,757	6,023,427	2,345,153	2,388,736
<b>Profit before Tax</b>	<b>120,995,137</b>	<b>120,468,541</b>	<b>46,903,059</b>	<b>47,774,711</b>
<b>Less: Income Tax Expenses</b>	<b>42,348,298</b>	<b>42,163,990</b>	<b>16,416,071</b>	<b>16,721,149</b>
Current Tax	34,856,070	34,129,144	13,959,222	14,042,997
Deferred Tax	7,492,228	8,034,845	2,456,849	2,678,152
<b>Net Profit after Tax</b>	<b>78,646,839</b>	<b>78,304,552</b>	<b>30,486,989</b>	<b>31,053,562</b>
<b>Earnings per Share (EPS)</b>	<b>1.22</b>	<b>1.22</b>	<b>0.47</b>	<b>0.48</b>

The annexed notes form an integral part of these financials.

sd/-  
Chief Financial Officer

sd/-  
Company Secretary

sd/-  
Managing Director

sd/-  
Chairman

Dated: April 28, 2019  
Place: Dhaka

**Silco Pharmaceuticals Limited**  
**Statement of Changes in Equity**  
**For the period ended March 31, 2019**

*(Amount in Taka)*

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as at July 01, 2018	643,700,000	1,097,376,872	1,741,076,872
Net Profit during the period	-	78,646,839	78,646,839
<b>Balance as on March 31, 2019</b>	<b>643,700,000</b>	<b>1,176,023,711</b>	<b>1,819,723,711</b>

**Statement of Changes in Equity**  
**For the period ended March 31, 2018**

*(Amount in Taka)*

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as at July 01, 2017	643,700,000	992,012,653	1,635,712,653
Net Profit during the period	-	78,304,552	78,304,552
<b>Balance as on March 31, 2019</b>	<b>643,700,000</b>	<b>1,070,317,205</b>	<b>1,714,017,205</b>

sd/-  
**Chief Financial Officer**

sd/-  
**Company Secretary**

sd/-  
**Managing Director**

sd/-  
**Chairman**

Dated: April 28, 2019  
Place: Dhaka

**Silco Pharmaceuticals Limited**  
**Statement of Cash Flows**  
**For the period ended March 31, 2019**

Particulars	Amount in Taka	
	01.07.2018 to 31.03.2019	01.07.2017 to 31.03.2018
<b>A. Cash Flows from Operating Activities</b>		
Cash received from Customers	633,481,620	565,936,084
Cash received from Non-operating income	150,360	292,168
Cash Paid to Suppliers	(434,808,318)	(428,872,877)
Cash Paid to Employees	(73,656,060)	(82,071,405)
Cash Paid to Others	(51,633,278)	(46,134,279)
Income Tax Paid	(807,822)	(866,505)
<b>Net cash flows from operating activities</b>	<b><u>72,726,502</u></b>	<b><u>8,283,185</u></b>
<b>B. Cash Flows from Investing Activities</b>		
Acquisition of Property, Plant & Equipment	(2,590,753)	(412,375)
Cash Payments for Capital Work-in-Progress	(72,899,210)	(6,049,050)
<b>Net cash flows from investing activities</b>	<b><u>(75,489,963)</u></b>	<b><u>(6,461,425)</u></b>
<b>C. Cash Flows from Financing Activities</b>		
Share Money Deposit (NRB)	347,485,000	-
Net Payment for Financial Expenses	(727,676)	(952,769)
Net Received/(Payment) in Long Term Loan	-	(7,326,431)
<b>Net Cash flows from financing activities</b>	<b><u>346,757,324</u></b>	<b><u>(8,279,200)</u></b>
<b>D. Net Increase/(Decrease) Cash and Cash Equivalents (A+B+C)</b>	<b><u>343,993,862</u></b>	<b><u>(6,457,439)</u></b>
E. Opening Cash and Cash Equivalents	15,662,446	17,675,005
<b>F. Closing Cash and Cash Equivalents (D+E)</b>	<b><u>359,656,308</u></b>	<b><u>11,217,565</u></b>
<b>Net Operating Cash Flows Per Share (NOCFPS)</b>	<b><u>1.13</u></b>	<b><u>0.13</u></b>

sd/-  
**Chief Financial Officer**

sd/-  
**Company Secretary**

sd/-  
**Managing Director**

sd/-  
**Chairman**

Dated: April 28, 2019  
Place: Dhaka